Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesMonoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin DrugsAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype BHuman monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutantsHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesCombination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants.Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virusPostnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strainsStructure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage.Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody responseCharacterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera.Monoclonal antibody-based candidate therapeutics against HIV type 1.In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteinsDynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance.Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?Dissecting the humoral immune response to simian immunodeficiency virus: mechanisms of antibody-mediated virus neutralization.Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.Viral sequence diversity: challenges for AIDS vaccine designs.Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitorsMolecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A.Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.Antibody-based HIV-1 vaccines: recent developments and future directions.Anti-HIV Passive Immunization: New Weapons in the Arsenal.Novel, Broadly Reactive Anticapsular Antibodies against Carbapenem-Resistant Klebsiella pneumoniae Protect from Infection.Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine?
P2860
Q24561905-CDF221B6-440B-4FD8-A449-AFF3D4319FD6Q26863621-F34B3EDA-2F4B-4466-B8FF-CE13FB7E1D0BQ27469855-AB231948-64C1-45EA-AE7C-3A80A2102203Q28469023-8B85A320-BC6B-4904-A48F-A768FC1C70A3Q28768526-48143D40-8382-4B02-9550-AA9BA26020D1Q29619015-6A165646-C6AB-4B46-B33E-5E2DC5FF6E1CQ30377663-EB2FB177-9422-4421-B227-0A6D4B7CB446Q33647608-B2EDF178-5BB7-463A-A739-A4F028E48401Q33809225-C7A79863-0237-40F6-9B82-879342E73D54Q33852768-A39A6C11-31E5-4961-96D7-270598AABDCDQ33870236-7E50566F-62BD-4545-9004-D6AE66207247Q33984358-F6AF252B-A1AB-43F1-A886-4A1BFB9446B4Q34045535-446D7BE6-2BD8-49B5-89B5-E95C33ED9C44Q34338411-12D3470F-EF39-4583-BEA5-A7AB1CCA97FFQ34344205-041C6FC5-AB16-4E7B-BED1-4AA401AD364AQ34357078-B26903F7-FA08-4A1C-8C92-F4A0830F9378Q34781840-A6FAB5A3-BD11-43B9-A283-FB9AD8822BFEQ35540731-9367DCFD-62AE-419A-8FAE-6E7AFFF1C078Q35904501-1539C636-CE6C-4AAF-8AEC-DE825F27C92FQ35947769-E2619AA3-6C2E-440B-86EC-7540F6AC0D1FQ35985896-9F25B42F-B2C4-457B-8261-042BD89AE50BQ35992786-6E8CA5FE-3C0C-43F7-9795-FAA0A4EAD135Q36404194-ABB6502E-F2C3-42D6-8F88-976A32347B80Q36751578-B7776BD5-901C-4F85-BCDF-386F4B95936FQ36827300-E22DE839-75AD-4AD3-A29B-41F1841E3D3BQ37316023-2DCE6396-09DD-4020-BF4B-B68E680A2501Q39454698-C25E9B6B-8A8F-4FBF-B21E-CA93F3C5819DQ39748810-1FE8EFCB-1B3E-4395-9A0A-60AAE1C0AE33Q39933471-5D9D6EF1-5E01-466C-940F-D32D11277055Q40061368-AB60059D-9559-4A46-867A-3E76603E6B2BQ40721814-D1571BD5-6608-4A8F-BC73-3E9A42960E75Q42572387-C9A9B5E4-F9B5-48EE-A03D-D107BC3A1AA9Q42738983-E8DDFCB0-2E6F-49F4-B72E-F2F6C41557C5Q47592375-778ECF94-8638-40F6-B18C-1566F21129ABQ52609091-393B83E0-9943-42C7-AAF5-893FEAF29FD4Q55000969-242232A2-1162-414B-A3A7-DAB2134B6F25
P2860
Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Synergistic neutralization of ...... virus type 1 immunoglobulins.
@ast
Synergistic neutralization of ...... virus type 1 immunoglobulins.
@en
type
label
Synergistic neutralization of ...... virus type 1 immunoglobulins.
@ast
Synergistic neutralization of ...... virus type 1 immunoglobulins.
@en
prefLabel
Synergistic neutralization of ...... virus type 1 immunoglobulins.
@ast
Synergistic neutralization of ...... virus type 1 immunoglobulins.
@en
P2093
P2860
P1433
P1476
Synergistic neutralization of ...... virus type 1 immunoglobulins.
@en
P2093
H Katinger
L Cavacini
M R Posner
R M Ruprecht
S Zolla-Pazner
P2860
P304
P577
1998-04-01T00:00:00Z